ACUTE MYELOID-LEUKEMIA EXPRESSING T-CELL ANTIGENS - CLINICOHEMATOLOGICAL REPORT ON 6 CASES

被引：15

作者：

FERRARA, F

FINIZIO, O

DEROSA, C

MELE, G

METTIVIER, V

RAMETTA, V

SPADA, OA

DELVECCHIO, L

机构：

[1] Division of Hematology, T.E.R.E. Section of Hematology Blood Transfusion Center, Cardarelli General Hospital, Naples

来源：

LEUKEMIA & LYMPHOMA | 1990年 / 3卷 / 03期

关键词：

Acute myeloid leukemia; Hybrid leukemia; Surface immunophenotype; T-cell markers;

D O I：

10.3109/10428199009050999

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a series of 107 patients suffering from acute myeloid leukemia (AML), blast cells from six patients were found to simultaneously express CD2 and CD7 antigens along with CD13, CD33, and CDw 65 in various combinations. The frequency of the expression of both lymphoid markers recurred with a higher incidence than that anticipated by multiplying single antigens frequency. The clinical and hematologic features from CD2+CD7 + AML patients were studied as well as compared with those of CD2-CD7- AML patients observed in the same period. Morphologically, bone marrow smears from the AML hybrid subset showed a preponderant population of agranular blasts along with a minority of typical myeloid cells, characterized by larger amount of cytoplasm and, in three cases, by rare but distinct Auer Rods. In all cases more than 3% of blast cells were positive for myeloperoxidases and all samples were classified as M1 according to FAB classification. Clinically, CD2 + /CD7 + patients presented with a higher incidence of adenopathy and meningeal leukemia than did patients with CD2 + /CD7 - AML and were characterized by poor response to therapy in terms of both achievement and duration of remission. We conclude that simultaneous expression of CD2 and CD7 in AML is a non random event, recurring in more than 5% of cases and is associated with distinct clinical and hematologic features. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：217 / 222

页数：6

共 23 条

[1]

Maitreyan V., Gale R.P., What is hybrid acute leukemia? (Editorial), Leuk. Res., 9, pp. 725-728, (1989)

[2]

Gale R.P., Ben Bassat I., Hybrid acute leukemia. (Annotation), Br. J. Haematol, 65, pp. 261-264, (1987)

[3]

Stass S.A., Mirro J., Lineage heterogeneity in acute leukemia: acute mixed-lineage leukemia and lineage switch, Clin. Haematol, 15, pp. 811-827, (1986)

[4]

Del Vecchio L., Schiavone E.M., Ferrara F., Pace E., Lo Pardo C., Pacetti M., Russo M., Cirillo D., Vacca C., Immunodiagnosis of acute leukemia displaying ectopic antigens: proposal for a classification of promiscuous phenotypes, Am. J. Hematol, 31, pp. 173-180, (1989)

[5]

Mirro J., Kitchingman G.R., Scott C.S., The morphology cytochemistry, molecular characteristics and clinical significance of acute mixed lineage leukemia, Leukemia Cytochemistry and Diagnosis: Principles and Practice, pp. 155-179, (1989)

[6]

Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan J.M., Proposed revised criteria for the classification of acute myeloid leukemia, Ann. Int. Med, 103, pp. 626-629, (1985)

[7]

Scott C.S., Cytochemical and Immunocytochemic Techniques, Leukemia Cytochemistry and Diagnosis: Principles and Practice, pp. 362-379, (1989)

[8]

Knapp W., Dorken B., Rieber P., Schmidt R.E., Stein H., von dem Borne A.E.G.K., CD antigens 1989, Blood, 74, pp. 1448-1450, (1989)

[9]

Greaves M.F., Target cells, cellular phenotypes, and lineage fidelity in human leukemia, J. Cell. Physiol. (Suppl), 1, pp. 113-125, (1982)

[10]

Greaves M.F., Chan L.C., Furley S.M., Watt S.M., Molgaard H.V., Lineage promiscuity in hemopoietic differentiation and Leukemia, Blood, 67, pp. 1-11, (1986)

← 1 2 3 →